# US 12,196,756 B2 · Lectin-based diagnostics of cancers > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,196,756 B2 - Document ID: US12196756B2 - Status: Granted - Kind: B2 - Application number: 16/318,035 - Filed: 2017-07-14 - Published: 2021-09-09 - Granted: 2025-01-14 - Earliest claimed: 2016-07-14 - Assignees: Uniogen Oy - Applicants: Kaivogen Oy - Inventors: Kamlesh Gidwani; Kim Pettersson; Henna Kekki - Web page: https://patentgrep.com/patent/US12196756B2 ## CPC - G01N 33/57525: of the liver or pancreas - G01N 33/57515: of the breast - G01N 33/57535: of the large intestine, e.g. colon, rectum or anus - G01N 33/57555: of the prostate - G01N 2333/4724: Lectins - G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 - G01N 2400/00: Assays, e.g. immunoassays or enzyme assays, involving carbohydrates - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present disclosure relates to non-invasive diagnostics of cancers, such as breast cancer, colorectal cancer, pancreatic cancer and prostate cancer, on the basis of altered glycosylation patterns of cancer-associated biomarkers. ## Claims ### Claim 1 A method for treating pancreatic cancer in a subject in need thereof, said method comprising: (a) assaying a sample obtained from the subject to detect a level of a Carbohydrate antigen 19-9 (CA19-9) glycoform that binds to Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), wherein the CA19-9 glycoform is CA19-9DC-SIGN, and wherein a CA19-9 specific antibody is used as a capturing agent and DC-SIGN as a detectably labelled tracer, or wherein DC-SIGN is used as a capturing agent and a CA19-9 specific antibody as a detectably labelled tracer; (b) comparing the detected level of said CA19-9DC-SIGN in said sample with that of (i) a healthy control sample, (ii) a benign control sample, or (iii) a predetermined threshold value; and (c) when the detected level of said CA19-9DC-SIGN in said sample is increased compared to that of (i) said healthy control sample, (ii) said benign control sample, or (iii) said predetermined threshold value, treating said subject for said pancreatic cancer with surgery, radiation therapy, chemotherapy, or any combination thereof. ### Claim 2 (depends on 1) The method according to claim 1, further comprising: monitoring said pancreatic cancer, wherein said monitoring is carried out by repeating the assaying step at least twice at different time points to determine if the level of CA19-9DC-SIGN in said sample is increased compared to one or more earlier samples obtained from the same subject or compared to that of said healthy control sample, said benign control sample, or said predetermined threshold value. ### Claim 3 (depends on 2) The method according to claim 2, further comprising: monitoring response to treatment, monitoring relapse of said cancer, or monitoring recurrence of said pancreatic cancer. ### Claim 4 (depends on 1) The method according to claim 1, where in the assaying step comprises: subjecting said sample to an antibody specific for CA19-9 in order to capture CA19-9 contained in the sample; subjecting said captured CA19-9 to DC-SIGN; and measuring the level of binding of said captured CA19-9 to said DC-SIGN. ### Claim 5 (depends on 1) The method according to claim 1, wherein the assaying step comprises: subjecting said sample to DC-SIGN in order to capture CA19-9DC-SIGN contained in the sample; subjecting said captured CA19-19DC-SIGN to an antibody specific for CA19-9; and measuring the level of binding of said captured CA19-9DC-SIGN to the antibody specific for CA19-9. ### Claim 6 (depends on 4) The method according to claim 4, wherein either said DC-SIGN or said CA19-9 specific antibody is immobilized on a nanoparticle. ### Claim 7 (depends on 1) The method according to claim 1, wherein said sample is selected from the group consisting of urine, blood, serum, plasma, peritoneal cavity fluid, and tissue samples. ### Claim 8 (depends on 1) The method according to claim 1, comprising: immobilizing said DC-SIGN on a nanoparticle or labelling said DC-SIGN with a detectable label. ### Claim 9 (depends on 6) The method according to claim 6, wherein all dimensions of said nanoparticle are less than about 1000 nm. ### Claim 10 (depends on 9) The method according to claim 9, wherein said nanoparticle is selected from the group consisting of protein nanoparticles, mineral nanoparticles, glass nanoparticles, nanoparticle crystals, metal nanoparticles, plastic nanoparticles, polystyrene nanoparticles, poly (ethylene glycol) nanoparticles, polyethylene nanoparticles, poly (acrylic acid) nanoparticles, poly (methyl methacrylate) nanoparticles, polysaccharide nanoparticles, colloidal gold nanoparticles, silver nanoparticles, quantum dots, carbon nanoparticles, porous silica nanoparticles, and liposomes. ### Claim 11 (depends on 9) The method according to claim 9, wherein said nanoparticle is composed of upconverting phosphorus (UCP) or is doped with a lanthanide chelate. ### Claim 12 (depends on 1) The method according to claim 1, wherein the detected level of said CA19-9DC-SIGN is determined as increased if its level in said sample is at least about 1.5 times that of said healthy control sample, said benign control sample, or said predetermined threshold value.